Christina Schröder1, Rita Engenhart-Cabillic2, Hilke Vorwerk2, Michael Schmidt3, Winfried Huhnt3, Eyck Blank3, Dietrich Sidow3, André Buchali3. 1. Clinic for Radiotherapy and Radiation Oncology, University Clinic Giessen and Marburg, Marburg, Germany;; Clinic for Radiotherapy and Radiation Oncology, Ruppiner Kliniken GmbH, Neuruppin, Germany. 2. Clinic for Radiotherapy and Radiation Oncology, University Clinic Giessen and Marburg, Marburg, Germany ; 3. Clinic for Radiotherapy and Radiation Oncology, Ruppiner Kliniken GmbH, Neuruppin, Germany.
Abstract
BACKGROUND: The purpose of this prospective randomized trial is to determine which constellation of dose and corresponding volume of the lung tissue-either a lot to a little or a little to a lot-should be preferred to ensure the best possible outcome for patients with thoracic carcinomas. METHODS: From Apr 2012 to Oct 2015, 81 patients with NSCLC, SCLC or esophageal carcinoma were randomized and treated with either a 4-field-IMRT or a VMAT technique with or without additional chemotherapy. Data regarding clinical outcome, pulmonary function tests (PFT) and quality of life (QoL) was collected before RT, 6 weeks, 12 weeks and 6 months after treatment, QoL data additionally 1 year post RT. Follow up CTs were done 12 weeks and 6 months after RT. RESULTS: There is no significant difference regarding the local (P=0.954) and distant (P=0.206) outcome, side effects (all P>0.05) or survival (P=0.633) at any follow-up appointment. The comparison of the PFT shows a statistically significant difference for the DLCO 6 weeks post RT (P=0.028). All other parameters do not differ significantly at any follow up appointment. Regarding the QoL there is no statistically significant difference at any follow up appointment (P>0.1). There is a statistically significant difference between the mean density of the lung parenchyma at 12 weeks (P<0.0005) and 6 months post RT (P<0.0005). CONCLUSIONS: Since there is no significant and relevant difference between both treatment arms regarding PFT, clinical outcome and QoL it does not seem to relevant how the DVH is shaped exactly as long as established dose constraints for the organs at risk are respected. As to whether the difference between the CT density changes is clinically relevant further analysis is needed.
RCT Entities:
BACKGROUND: The purpose of this prospective randomized trial is to determine which constellation of dose and corresponding volume of the lung tissue-either a lot to a little or a little to a lot-should be preferred to ensure the best possible outcome for patients with thoracic carcinomas. METHODS: From Apr 2012 to Oct 2015, 81 patients with NSCLC, SCLC or esophageal carcinoma were randomized and treated with either a 4-field-IMRT or a VMAT technique with or without additional chemotherapy. Data regarding clinical outcome, pulmonary function tests (PFT) and quality of life (QoL) was collected before RT, 6 weeks, 12 weeks and 6 months after treatment, QoL data additionally 1 year post RT. Follow up CTs were done 12 weeks and 6 months after RT. RESULTS: There is no significant difference regarding the local (P=0.954) and distant (P=0.206) outcome, side effects (all P>0.05) or survival (P=0.633) at any follow-up appointment. The comparison of the PFT shows a statistically significant difference for the DLCO 6 weeks post RT (P=0.028). All other parameters do not differ significantly at any follow up appointment. Regarding the QoL there is no statistically significant difference at any follow up appointment (P>0.1). There is a statistically significant difference between the mean density of the lung parenchyma at 12 weeks (P<0.0005) and 6 months post RT (P<0.0005). CONCLUSIONS: Since there is no significant and relevant difference between both treatment arms regarding PFT, clinical outcome and QoL it does not seem to relevant how the DVH is shaped exactly as long as established dose constraints for the organs at risk are respected. As to whether the difference between the CT density changes is clinically relevant further analysis is needed.
Entities:
Keywords:
Lung neoplasms; intensity modulated radiotherapy (IMRT); quality of life (QoL); radiation pneumonitis (RP); respiratory function tests
Authors: Katrien De Jaeger; Yvette Seppenwoolde; Liesbeth J Boersma; Sara H Muller; Paul Baas; José S A Belderbos; Joos V Lebesque Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: Jose L Lopez Guerra; Daniel R Gomez; Yan Zhuang; Lawrence B Levy; George Eapen; Hongmei Liu; Radhe Mohan; Ritsuko Komaki; James D Cox; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-13 Impact factor: 7.038
Authors: Matthias Guckenberger; Rainer J Klement; Larry L Kestin; Andrew J Hope; Jose Belderbos; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Inga S Grills Journal: Int J Radiat Oncol Biol Phys Date: 2012-11-12 Impact factor: 7.038
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Ramesh Gopal; George Starkschall; Susan L Tucker; James D Cox; Zhongxing Liao; Michael Hanus; Jason F Kelly; Craig W Stevens; Ritsuko Komaki Journal: Int J Radiat Oncol Biol Phys Date: 2003-05-01 Impact factor: 7.038
Authors: Javier Jaén; Gonzalo Vázquez; Enrique Alonso; Maria D De Las Peñas; Laura Díaz; Manuel De Las Heras; José F Pérez-Regadera Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-25 Impact factor: 7.038
Authors: Sinisa Stanic; Rebecca Paulus; Robert D Timmerman; Jeff M Michalski; Robert B Barriger; Andrea Bezjak; Gregory M M Videtic; Jeffrey Bradley Journal: Int J Radiat Oncol Biol Phys Date: 2014-04-01 Impact factor: 7.038
Authors: K Vekens; S Verbanck; C Collen; G Storme; K Barbé; M De Ridder; E Vanderhelst Journal: Strahlenther Onkol Date: 2019-07-12 Impact factor: 3.621
Authors: Sander Roberti; Flora E van Leeuwen; Cécile M Ronckers; Inge M Krul; Florent de Vathaire; Cristina Veres; Ibrahima Diallo; Cécile P M Janus; Berthe M P Aleman; Nicola S Russell; Michael Hauptmann Journal: J Natl Cancer Inst Date: 2022-09-09 Impact factor: 11.816